Industry Supported Session Programmes


Wednesday,16 MAY 2018

REDEFINING STROKE PREVENTION IN AF AND EVEN BEYOND
SYMPOSIUM IS ORGANISED AND SUPPORTED BY Bayer

Wednesday, 16 May, 12:45-14:15, Hall K1

Chairs: Mike Sharma, Canada and John Camm, UK

Opening remarks-Introduction 
Mike Sharma, Canada 

Optimizing Stroke Prevention in AF Patients with Multiple Morbidities and why Accurate Medication Really Matters
John Camm, UK

A new Chapter for Stroke Prevention with a NOAC: Vascular Protection
Mike Sharma, Canada 

Practical challenges in Secondary Stroke Prevention. Do we need inter-disciplinary collaboration?         
Darius Nabavi, Germany

New Insights in Stroke Management     
Graeme Hankey, Australia

Discussion and Q&A
All

Closing Remarks

John Camm, UK

--------------------------------------------------------------------------------------------------------

WHEN TO LOOK FOR A RARE CAUSE OF STROKE
SYMPOSIUM IS ORGANISED AND SUPPORTED BY Shire

Wednesday, 16 May, 12:45-14:15, Hall K3 

Chair: Ricardo Reisin, Argentina

Welcome and Introduction to Fabry Disease

Ricardo Reisin, Argentina

Genotype-Phenotype Correlations in Fabry Disease: A Neurologist's View

Tobias Böttcher, Germany

Differential Diagnosis of Fabry Disease: Neuroimaging Perspective

Georgios Tsivgoulis, Greece

Stroke in Fabry Disease: Pathogenesis and Treatment

Ricardo Reisin, Argentina

Q&A and Close

All faculty

--------------------------------------------------------------------------------------------------------

STROKE PREVENTION AND TREATMENT:  NEW INSIGHTS INTO NOACS AND REVERSAL

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Boehringer Ingelheim

Wednesday, 16 May, 12:45-14:15, Hall H

Co-Chairs: Stephen Davis, Australia and Hans-Christoph Diener, Germany

Managing Stroke Today: Challenges and Opportunities

Stephen Davis, Australia

Stroke Prevention in AF: How Can We Optimize Anticoagulation?

Q&A

Danilo Toni, Italy

Stroke Treatment: Can Dabigatran Reversal Improve Outcomes?

Q&A

Martin Grond, Germany

Embolic Stroke of Undetermined Source (ESUS): Concept and Current Treatment Options 

Q&A

Hans-Christoph Diener, Germany

Closing summary

Stephen Davis, Australia and Hans-Christoph Diener, Germany

--------------------------------------------------------------------------------------------------------

NOVEL STROKE PROPHYLAXIS STRATEGIES: WHEN SHOULD CARDIAC OCCLUSION THERAPIES BE CONSIDERED?
SYMPOSIUM IS ORGANISED AND SUPPORTED BY Abbott

Wednesday, 16 May, 12:45-14:15, Hall E4 

Chairs: Per Wester, Sweden and Jeffrey Saver, USA

Introduction and Objectives

Per Wester, Sweden

When is The Heart at The Origin of Ischaemic Strokes?

Jeffrey Saver, USA

Occlusion Procedures Safety and Efficacy: It's Not Open Heart Surgery

Jacob Odenstedt, Sweden

LAA Occlusion: An Alternative Therapy for Reducing the Risk of Stroke in AF Patients.

Per Wester, Sweden

Which Patients for PFO Closure: Lessons Learned of The Most Recent Randomized Clinical Trials and Implications for The Heart & Brain Team

Mikael Dellborg, Sweden

Will the New Evidence Change Clinical Decision Making and Guidelines in Neurology?

Christian Gerloff, Germany

Take Home Message

Jeffrey Saver, USA

--------------------------------------------------------------------------------------------------------

MORE PATIENTS, LESS DISABILITY

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Stryker

Wednesday, 16 May, 12:45-14:15, Hall E1

Moderator: Tudor Jovin, USA

The DAWN™ Trial - a New Era

Raul G. Nogueira, USA

The Trevo™ Retriever Registry: From Clinical Commitment to Everyday Practice

Marc Brockman, Germany

Ischemic Stroke Treatment - The Next Frontier

Vincent Costalat, France


Thursday,17 MAY 2018

MANAGEMENT OF ATRIAL FIBRILLATION, STROKE, AND BLEEDING: EVIDENCE FROM CLINICAL PRACTICE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY MSD and Daiichi-Sankyo 

Thursday,17 May, 12:45-14:15, Hall H

Chair: Raffaele De Caterina, Italy

Welcome and Introduction

Raffaele De Caterina, Italy

Bleeding & Efficacy – Is There a Difference Between the Compounds?

Raffaele De Caterina, Italy

Screening for Atrial Fibrillation to Prevent Strokes – Where Are We Now?

Marten Rosenqvist, Sweden

NOAC-Related Intracranial Hemorrhage – Risk, Clinical Presentation, and Predictors

Hanne Christensen, Denmark

Oral Anticoagulants: What Did We Learn in Clinical Practice?

Jan Steffel, Switzerland

NOACs: Can the Effect Be Reversed in Acute Situations?

Hans-Christoph Diener, Germany

Faculty Round Table and Q&A

--------------------------------------------------------------------------------------------------------

NEW EVIDENCE FOR MULTI-MODAL TREATMENT CONCEPTS IN POST-STROKE RECOVERY

SYMPOSIUM IS ORGANISED AND SUPPORTED BY EVER Pharma

Thursday,17 May, 12:45-14:15, Hall E1

Chair: Wolf-Dieter Heiss, Germany

Neuroprotection and Neurorepair after Stroke: Example Cerebrolysin

Michael Brainin, Austria

Noninvasive Brain Stimulation & multi-modal treatment concepts
Andreas Winkler, Austria

Anticorrelated processes in neurobiology - possible consequences for neurorehabilitation strategies
Dafin Muresanu, Romania

New evidence from a recent meta-analysis in in acute ischemic Stroke
Natan Bornstein, Israel

--------------------------------------------------------------------------------------------------------

EXPERIENCE FROM TODAY FOR THE STROKE CARE OF THE FUTURE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Boehringer Ingelheim

Thursday,17 May, 12:45-14:15, Hall K2

Chair: Georgios Tsivgoulis, Greece

Clinical updates on acute ischaemic stroke reperfusion strategies

Götz Thomalla, Germany & Peter Ringleb, Germany

Strategic planning of stroke unit coverage and quality improvement, the Austrian experience

Julia Ferrari, Austria  

Quality monitoring to improve acute stroke care on a national level, the Czech experience

Ales Tomek, Czech Republic

Creating the link between stroke ready hospitals and emergency medical services, the Slovakian experience

Matej Polak, Slovakia 

Simulation training to optimise stroke care, experience from the ESO simulation committee

Paola Santalucia, Italy

--------------------------------------------------------------------------------------------------------

THE PATIENT JOURNEY THROUGH STROKE: FOCUS ON PREVENTION OF AF-RELATED STROKE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY BMS Pfizer Alliance 

Thursday,17 May, 12:45-14:15, Hall K3

Chair: Arne Lindgren, Sweden

The Stroke Patient Journey: Does It Only Begin in The Emergency Room?

Arne Lindgren, Sweden

Evolving Practical Management of Acute Ischemic Stroke

Didier Leys, France

AF Detection After a Stroke – When and How Intensive?

Roland Veltkamp, UK

Roadmap of Stroke Prevention – Role of The Noacs in Improving Patient Outcomes

Stefan Hohnloser (Germany) and Arne Lindgren (Sweden)

Road Ahead – What Have We Learnt? What More is There to Do?

Arne Lindgren, Sweden

Q&A

All

--------------------------------------------------------------------------------------------------------

MEDTRONIC CARE CONTINUUM: PATIENT PATHWAY

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Medtronic

Thursday, 17 May, 12:45-14:15, Hall K1

Moderator: Antonio Dávalos, Spain

RAPID: Advanced Imaging in Patient Selection for Mechanical Thrombectomy

Greg Albers, USA

Atrial Fibrillation in Stroke Patients: Are You Looking Long Enough?

Martin Köhrmann, Germany

ITB Therapy for Post Stroke Spasticity - New Evidence for an Unmet Need

Geoffrey Cloud, Australia

Panel Discussion



Keep Me Updated